Fundraising FoxVesalius Biocapital III Partners SàRL
Venture capitalContern · Series B–Late Stage · 11 people tracked
Find your way into Vesalius Biocapital III Partners SàRL
Sign up to see every warm intro you have to Vesalius Biocapital III Partners SàRL
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vesalius Biocapital III Partners SàRL team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Vesalius Biocapital invests in later-stage life sciences companies across Europe, targeting drug development, medical devices and diagnostics, and eHealth/mHealth (digital health) sectors. The firm looks for portfolio companies that address unmet medical and market needs and are built on strong intellectual property protection. Its active fund, Vesalius Biocapital III, reached a final close in May 2019 with €120 million in commitments.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from the firm's website & public directories
Frequently asked questions
- What stage does Vesalius Biocapital III Partners SàRL invest at?
- Vesalius Biocapital III Partners SàRL invests at the Series B, Series C, Growth, Late Stage stages.
- What is Vesalius Biocapital III Partners SàRL's typical check size?
- Vesalius Biocapital III Partners SàRL typically writes checks of $10.8M.
- What sectors does Vesalius Biocapital III Partners SàRL focus on?
- Vesalius Biocapital III Partners SàRL focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Vesalius Biocapital III Partners SàRL located?
- Vesalius Biocapital III Partners SàRL is headquartered in Contern, LU.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.